151 related articles for article (PubMed ID: 7628594)
1. In vitro drug sensitivity of leukemic progenitors and P-glycoprotein expression in adult acute myeloid leukemia: correlation with induction treatment outcome.
Basara N; Radosević-Radojković N; Colović M; Bosković D; Rolović Z
Eur J Haematol; 1995 Aug; 55(2):83-7. PubMed ID: 7628594
[TBL] [Abstract][Full Text] [Related]
2. Effect of the protein kinase C inhibitor staurosporine on chemosensitivity to daunorubicin of normal and leukemic fresh myeloid cells.
Laredo J; Huynh A; Muller C; Jaffrézou JP; Bailly JD; Cassar G; Laurent G; Demur C
Blood; 1994 Jul; 84(1):229-37. PubMed ID: 7912555
[TBL] [Abstract][Full Text] [Related]
3. Correlation of MDR1/P-170 expression with daunorubicin uptake and sensitivity of leukemic progenitors in acute myeloid leukemia.
Campos L; Guyotat D; Jaffar C; Solary E; Archimbaud E; Treille D
Eur J Haematol; 1992 May; 48(5):254-8. PubMed ID: 1353726
[TBL] [Abstract][Full Text] [Related]
4. Contrasting in vitro effects for the combination of fludarabine, cytosine arabinoside (Ara-C) and granulocyte colony-stimulating factor (FLAG) compared with daunorubicin and Ara-C in P-glycoprotein-positive and P-glycoprotein-negative acute myeloblastic leukaemia.
Higashi Y; Turzanski J; Pallis M; Russell NH
Br J Haematol; 2000 Nov; 111(2):565-9. PubMed ID: 11122104
[TBL] [Abstract][Full Text] [Related]
5. The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis.
van der Holt B; Löwenberg B; Burnett AK; Knauf WU; Shepherd J; Piccaluga PP; Ossenkoppele GJ; Verhoef GE; Ferrant A; Crump M; Selleslag D; Theobald M; Fey MF; Vellenga E; Dugan M; Sonneveld P
Blood; 2005 Oct; 106(8):2646-54. PubMed ID: 15994288
[TBL] [Abstract][Full Text] [Related]
6. Multivariate analysis of prognostic factors in acute myeloid leukemia: value of clonogenic leukemic cell properties.
Delmer A; Marie JP; Thevenin D; Cadiou M; Viguié F; Zittoun R
J Clin Oncol; 1989 Jun; 7(6):738-46. PubMed ID: 2715804
[TBL] [Abstract][Full Text] [Related]
7. Anthracycline drugs and MDR expression in human leukemia.
Pogliani EM; Belotti D; Rivolta GF; Maffè PF; Corneo G
Cytotechnology; 1996; 19(3):229-35. PubMed ID: 8862011
[TBL] [Abstract][Full Text] [Related]
8. Clinical significance of CD95, Bcl-2 and Bax expression and CD95 function in adult de novo acute myeloid leukemia in context of P-glycoprotein function, maturation stage, and cytogenetics.
Wuchter C; Karawajew L; Ruppert V; Büchner T; Schoch C; Haferlach T; Ratei R; Dörken B; Ludwig WD
Leukemia; 1999 Dec; 13(12):1943-53. PubMed ID: 10602414
[TBL] [Abstract][Full Text] [Related]
9. The in vitro growth patterns and drug sensitivities of leukemic blast progenitors among the subtypes of acute myelocytic leukemia.
Nara N; Chen GJ; Murohashi I; Tohda S; Imai Y; Tomiyama J; Nagata K; Suzuki T; Tanikawa S; Shiina S
Exp Hematol; 1992 Aug; 20(7):904-8. PubMed ID: 1628709
[TBL] [Abstract][Full Text] [Related]
10. MDR1 and BCRP1 expression in leukemic progenitors correlates with chemotherapy response in acute myeloid leukemia.
Ho MM; Hogge DE; Ling V
Exp Hematol; 2008 Apr; 36(4):433-42. PubMed ID: 18249061
[TBL] [Abstract][Full Text] [Related]
11. Correlation of drug sensitivity in vitro with clinical responses in childhood acute myeloid leukemia.
Dow LW; Dahl GV; Kalwinsky DK; Mirro J; Nash MB; Roberson PK
Blood; 1986 Aug; 68(2):400-5. PubMed ID: 3460647
[TBL] [Abstract][Full Text] [Related]
12. Human stem cell factor-antibody [anti-SCF] enhances chemotherapy cytotoxicity in human CD34+ resistant myeloid leukaemia cells.
Lu C; Hassan HT
Leuk Res; 2006 Mar; 30(3):296-302. PubMed ID: 16112192
[TBL] [Abstract][Full Text] [Related]
13. Relationship between the in vitro sensitivity to cytosine arabinoside of blast progenitors and the outcome of treatment in acute myeloblastic leukaemia patients.
Nara N; Suzuki T; Nagata K; Yamashita Y; Murohashi I; Adachi Y
Br J Haematol; 1988 Oct; 70(2):187-91. PubMed ID: 3191030
[TBL] [Abstract][Full Text] [Related]
14. Acid ceramidase promotes drug resistance in acute myeloid leukemia through NF-κB-dependent P-glycoprotein upregulation.
Tan SF; Dunton W; Liu X; Fox TE; Morad SAF; Desai D; Doi K; Conaway MR; Amin S; Claxton DF; Wang HG; Kester M; Cabot MC; Feith DJ; Loughran TP
J Lipid Res; 2019 Jun; 60(6):1078-1086. PubMed ID: 30962310
[TBL] [Abstract][Full Text] [Related]
15. Expression and functional activity of P-glycoprotein in adult acute myelogenous leukemia patients.
Nuessler V; Gullis E; Pelka-Fleischer R; del Valle F; Diem H; Beyerlein S; Zwierzina H; Wilmanns W
Ann Hematol; 1997; 75(1-2):17-26. PubMed ID: 9322679
[TBL] [Abstract][Full Text] [Related]
16. Comparative effects of G-CSF, GM-CSF and IL-3 on cytosine arabinoside- and daunorubicin-mediated cytotoxicity of acute myeloid leukemia cells and normal myeloid progenitors.
Waga K; Furusawa S; Nagashima S; Saito K; Shishido H
Int J Hematol; 1992 Aug; 56(1):17-27. PubMed ID: 1391803
[TBL] [Abstract][Full Text] [Related]
17. Aclarubicin plus cytosine arabinoside versus daunorubicin plus cytosine arabinoside in previously untreated patients with acute myeloid leukemia: a Danish national phase III trial. The Danish Society of Hematology Study Group on AML, Denmark.
Hansen OP; Pedersen-Bjergaard J; Ellegaard J; Brincker H; Boesen AM; Christensen BE; Drivsholm A; Hippe E; Jans H; Jensen KB
Leukemia; 1991 Jun; 5(6):510-6. PubMed ID: 2056774
[TBL] [Abstract][Full Text] [Related]
18. P-glycoprotein in primary acute myeloid leukemia and treatment outcome of idarubicin/cytosine arabinoside-based induction therapy.
Broxterman HJ; Sonneveld P; van Putten WJ; Lankelma J; Eekman CA; Ossenkoppele GJ; Pinedo HM; Löwenberg B; Schuurhuis GJ
Leukemia; 2000 Jun; 14(6):1018-24. PubMed ID: 10865967
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the proliferative activity and sensitivity to cytosine arabinoside of leukemic blast progenitors in acute myeloblastic leukemia at diagnosis and in relapse.
Nara N; Tohda S; Suzuki T; Nagata K; Tanikawa S; Imai Y; Tomiyama J; Shiina S
Acta Haematol; 1992; 88(1):17-21. PubMed ID: 1414157
[TBL] [Abstract][Full Text] [Related]
20. Cellular and pharmacologic aspects of drug resistance in acute myeloid leukemia.
Ross DD
Curr Opin Oncol; 1991 Feb; 3(1):21-9. PubMed ID: 1675126
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
